Rosuvastatin Improves Vaspin Serum Levels in Obese Patients with Acute Coronary Syndrome

• Main Authors: Hayder M. Al-kuraishy, Ali I. Al-Gareeb, Ali K. Al-Buhadilly
• Format: Article
• Language: English
• Published: MDPI AG 2018-01-01
• Series: Diseases
• Subjects: vaspin; acute coronary syndrome; NSTEMI; STEMI
• Online Access: http://www.mdpi.com/2079-9721/6/1/9

Adipose tissue-derived serine protease inhibitor (vaspin), which has endocrine and local roles in atherosclerosis growth, is also synthesized by adipose tissue; it was found that vaspin was negatively correlated with blood pressure in obese patients, while vaspin levels were decreased in endothelial dysfunction. The aim of the present study was to determine rosuvastatin modulation effects on serum vaspin levels in acute coronary syndrome (ACS) with class I obesity. A total number of seventy patients with acute coronary syndrome previously and currently treated with rosuvastatin was compared to 40 patients with IHD not treated by rosuvastatin as a control. Vaspin serum levels were higher in rosuvastatin-treated patients with acute coronary syndrome compared to the patients with acute coronary syndrome not treated by rosuvastatin, p < 0.01. Additionally, in the rosuvastatin-treated group, patients with STEMI showed higher vaspin serum levels compared to NSTEMI p < 0.01. Conclusion: Rosuvastatin significantly increases vaspin serum levels in acute coronary syndrome.